These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 14714697)
41. Enforcing pharmaceutical and biotech patent rights in China. Zhang YP; Deng MM Nat Biotechnol; 2008 Nov; 26(11):1235-40. PubMed ID: 18997760 [No Abstract] [Full Text] [Related]
42. Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries. Spectar JM Houst J Int Law; 2002; 24(2):227-78. PubMed ID: 16189914 [No Abstract] [Full Text] [Related]
43. Managing severe acute respiratory syndrome (SARS) intellectual property rights: the possible role of patent pooling. Simon JH; Claassen E; Correa CE; Osterhaus AD Bull World Health Organ; 2005 Sep; 83(9):707-10. PubMed ID: 16211163 [TBL] [Abstract][Full Text] [Related]
44. Challenges to human embryonic stem cell patents. Plomer A; Taymor KS; Scott CT Cell Stem Cell; 2008 Jan; 2(1):13-7. PubMed ID: 18371416 [TBL] [Abstract][Full Text] [Related]
45. WIPO’s Standing Committee on the Law of Patents meets in Geneva. Hemsley A Pharm Pat Anal; 2012 Jul; 1(3):239-40. PubMed ID: 24386666 [No Abstract] [Full Text] [Related]
46. Intellectual property. U.S. Patent Office casts doubt on Wisconsin stem cell patents. Holden C Science; 2007 Apr; 316(5822):182. PubMed ID: 17431141 [No Abstract] [Full Text] [Related]
47. Human genome carve-up continues. Gross M Curr Biol; 2005 Nov; 15(22):R904. PubMed ID: 16365942 [No Abstract] [Full Text] [Related]
49. A general approach for determining when to patent, publish, or protect information as a trade secret. Daizadeh I; Miller D; Glowalla A; Leamer M; Nandi R; Numark CI Nat Biotechnol; 2002 Oct; 20(10):1053-4. PubMed ID: 12355117 [No Abstract] [Full Text] [Related]
50. International panel considers global patent system needs reassessment. Ashraf H Lancet; 2002 Sep; 360(9336):858. PubMed ID: 12243929 [No Abstract] [Full Text] [Related]
51. Intellectual property law: a primer for scientists. Brown WM Mol Biotechnol; 2003 Mar; 23(3):213-24. PubMed ID: 12665692 [TBL] [Abstract][Full Text] [Related]
52. Intellectual property and the human genome (Part II). Kirby M Rev Derecho Genoma Hum; 2001; (15):65-83. PubMed ID: 11921893 [No Abstract] [Full Text] [Related]
53. To be or not IP? Exploring limits within patent law for the constitutionalization of intellectual property rights and the governance of synthetic biology in human health. Schneider I Rev Derecho Genoma Hum; 2012; (37):193-233. PubMed ID: 23520920 [TBL] [Abstract][Full Text] [Related]
54. The evolution of gene patents viewed from the United States Patent Office. Mossinghoff GJ Adv Genet; 2003; 50():13-21; discussion 507-10. PubMed ID: 14714684 [TBL] [Abstract][Full Text] [Related]
55. The Supreme Court's war on intellectual property. Gardner JN Nat Biotechnol; 2000 Jan; 18(1):101-2. PubMed ID: 10625402 [TBL] [Abstract][Full Text] [Related]
56. Patent prosecution in structural proteomics. Chan K; Fernandez D Assay Drug Dev Technol; 2004 Jun; 2(3):313-9. PubMed ID: 15285913 [TBL] [Abstract][Full Text] [Related]
57. Introduction: Access to life-saving medicines and intellectual property rights. Schroeder D Camb Q Healthc Ethics; 2011 Apr; 20(2):277-8. PubMed ID: 21435302 [No Abstract] [Full Text] [Related]
58. Will NIH patent bid cause "land rush"? Jenks S J Natl Cancer Inst; 1992 Jun; 84(12):920-1. PubMed ID: 1629911 [No Abstract] [Full Text] [Related]